Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 12, 2015, 35 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $688.88 to $5,444,250.00.

Highlighted Stocks Traded by Insiders:

Harris & Harris Group (TINY) - FREE Research Report

Jamison Douglas W, who is Chairman, CEO at Harris & Harris Group, bought 605 shares at $3.02 on Jan. 12, 2015. Following this transaction, the Chairman, CEO owned 195,029 shares meaning that the stake was boosted by 0.31% with the 605-share transaction.

Wolfe Daniel B, who is President at Harris & Harris Group, bought 360 shares at $3.02 on Jan. 12, 2015. Following this transaction, the President owned 145,651 shares meaning that the stake was boosted by 0.25% with the 360-share transaction.

Ushio Misti, who is Executive Vice President at Harris & Harris Group, bought 280 shares at $3.02 on Jan. 12, 2015. Following this transaction, the Executive Vice President owned 112,602 shares meaning that the stake was boosted by 0.25% with the 280-share transaction.

The shares most recently traded at $3.19, up $0.17, or 5.33% since the insider transaction. Historical insider transactions for Harris & Harris Group go as follows:

  • 4-Week # shares bought: 18,557
  • 12-Week # shares bought: 18,557
  • 24-Week # shares bought: 37,162

The average volume for Harris & Harris Group has been 114,800 shares per day over the past 30 days. Harris & Harris Group has a market cap of $95.3 million and is part of the financial sector and financial services industry. Shares are up 6.78% year-to-date as of the close of trading on Monday.

Harris & Harris Group, Inc. is a venture capital firm specializing in early stage investments. It is a BDC. Currently, there are no analysts who rate Harris & Harris Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TINY - FREE

TheStreet Quant Ratings

rates Harris & Harris Group as a

TheStreet Recommends

hold

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and notable return on equity. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and weak operating cash flow. Get the full

Harris & Harris Group Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Magellan Health (MGLN) - FREE Research Report

West Jeffrey N, who is SVP & Controller at Magellan Health, bought 289 shares at $51.03 on Jan. 12, 2015. Following this transaction, the SVP & Controller owned 8,858 shares meaning that the stake was boosted by 3.37% with the 289-share transaction.

The shares most recently traded at $60.79, up $9.76, or 16.06% since the insider transaction. Historical insider transactions for Magellan Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 18,400
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 18,400
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 18,400

The average volume for Magellan Health has been 180,300 shares per day over the past 30 days. Magellan Health has a market cap of $1.7 billion and is part of the health care sector and health services industry. Shares are down 0.62% year-to-date as of the close of trading on Monday.

Magellan Health, Inc. is engaged in the healthcare management business in the United States. The company has a P/E ratio of 21.8. Currently, there is 1 analyst who rates Magellan Health a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MGLN - FREE

TheStreet Quant Ratings

rates Magellan Health as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full

Magellan Health Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

HCC Insurance Holdings (HCC) - FREE Research Report

Schell Michael J, who is Executive Vice President at HCC Insurance Holdings, sold 15,264 shares at $53.59 on Jan. 12, 2015. Following this transaction, the Executive Vice President owned 50,722 shares meaning that the stake was reduced by 23.13% with the 15,264-share transaction.

The shares most recently traded at $54.26, up $0.67, or 1.23% since the insider transaction. Historical insider transactions for HCC Insurance Holdings go as follows:

  • 4-Week # shares sold: 15,668
  • 12-Week # shares sold: 19,668
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 19,668

The average volume for HCC Insurance Holdings has been 370,100 shares per day over the past 30 days. HCC Insurance Holdings has a market cap of $5.2 billion and is part of the financial sector and insurance industry. Shares are down 0.75% year-to-date as of the close of trading on Monday.

HCC Insurance Holdings, Inc. underwrites non-correlated specialty insurance products worldwide. The company operates in five segments: U.S. Property & Casualty, Professional Liability, Accident & Health, U.S. Surety & Credit, and International. The U.S. The stock currently has a dividend yield of 2.21%. The company has a P/E ratio of 11.6. Currently, there are 2 analysts who rate HCC Insurance Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HCC - FREE

TheStreet Quant Ratings

rates HCC Insurance Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

HCC Insurance Holdings Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null